Olema Pharmaceuticals, Inc. 2025 Annual Report — Key Highlights and Investor Insights

Company Overview

Olema Pharmaceuticals, Inc. (“Olema” or the “Company”) is a clinical-stage biopharmaceutical company based in San Francisco, CA, focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. The Company trades on the Nasdaq Global Select Market under the symbol OLMA.

Key Financial and Corporate Highlights

• Market Capitalization: As of June 30, 2025, Olema’s aggregate market value of common stock held by non-affiliates was approximately \$243.1 million.
• Outstanding Shares: As of March 11, 2026, Olema had 87,156,961 shares of common stock outstanding, excluding 13,599 shares issuable upon exercise of pre-funded warrants.
• Exchange: Olema’s common stock is registered and traded on the Nasdaq Global Select Market.
• Corporate Structure: Olema qualifies as a “smaller reporting company” under SEC rules, allowing it to take advantage of certain disclosure exemptions.

Business Risks & Forward-Looking Statements

Olema’s 2025 Annual Report contains numerous forward-looking statements that are subject to significant risks and uncertainties. These include statements regarding financial performance, sufficiency of cash, clinical trial progress, regulatory events, and potential commercialization. The Company explicitly warns investors that actual results may differ materially from those projected.

Risk Factor Summary — Price Sensitive Factors

• No Approved Commercial Products: Olema currently has no products approved for commercial sale, making it challenging for investors to evaluate the business and predict future success.
• Need for Additional Capital: The Company requires substantial additional capital to finance operations. If unable to raise capital on acceptable terms, Olema may be forced to delay or eliminate research and development programs, which could have a significant impact on share value.
• Macroeconomic and Geopolitical Risks: Unfavorable U.S. and global conditions could adversely affect business operations and financial results.
• Information Technology and Data Security Risks: If Olema’s IT systems or those of third-party partners are compromised, the Company could face regulatory investigations, litigation, fines, disruptions, reputational harm, and loss of revenue.
• Intellectual Property: Success depends on Olema’s ability to protect its proprietary technologies. Any failure in this area could impact competitive advantage and share price.
• Reliance on Third Parties: Olema relies on independent clinical investigators and contract research organizations (CROs) for non-clinical studies and clinical trials. Any failures or delays on their part could affect the regulatory approval and commercialization of key product candidates.
• Regulatory & Reporting Status: Olema is a “smaller reporting company” and may use certain SEC disclosure exemptions. This could make its securities less attractive and harder to compare with other public companies.

Potential Share Price Movers

• Capital Requirements:

  The need for substantial additional capital is a crucial risk. If Olema cannot raise funds when needed, it may have to scale back or discontinue key development programs, directly affecting future growth prospects and share value.

• Product Pipeline and Clinical Progress:

  Olema’s future value is heavily dependent on the progress and success of its clinical trials, particularly for lead candidates like palazestrant (OP-1250) and OP-3136. Any setbacks or positive developments in these trials could cause significant share price movements.

• Regulatory Risks and Data Security:

  The Company highlights possible adverse regulatory actions or breaches in data security, which could lead to penalties, litigation, and reputational harm — all of which may be price sensitive and materially affect investor sentiment.

• Macroeconomic Conditions:

  Unfavorable broader economic or geopolitical events may impact Olema’s financial condition and operational results, and thus its share price.

• Reporting Exemptions:

  As a smaller reporting company, Olema uses certain SEC exemptions. This reduced disclosure may make its stock less attractive to institutional investors and hinder comparison with larger peers.

Special Note for Investors

DOCUMENTS INCORPORATED BY REFERENCE: Portions of Olema’s definitive Proxy Statement for the 2026 Annual Meeting of Stockholders will be filed with the SEC and incorporated into this Annual Report, providing further key details on executive compensation, corporate governance, and related matters.

Disclaimer

This article is a summarization and interpretation of Olema Pharmaceuticals, Inc.’s 2025 Annual Report and is intended for informational purposes only. The information provided may contain forward-looking statements and is subject to change. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The author assumes no responsibility for any investment actions taken based on this summary.

View Olema Pharmaceuticals, Inc. Historical chart here